ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BVP Bioscience Vct

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type Share ISIN Share Description
Bioscience Vct LSE:BVP London Ordinary Share GB0031256109 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

BVCT Update

20/04/2006 8:02am

UK Regulatory


RNS Number:7083B
Medical Marketing Int'l Group PLC
20 April 2006




For Immediate Release              20 April 2006



            MMI agreement with Bioscience VCT becomes unconditional



Medical Marketing International Group plc ("MMI") (AIM: MMG), the Cambridge, UK-
based pharmaceutical development company focussed on cancer and infection, today
announces that it has reached unconditional agreement with Bioscience VCT plc
("the VCT") and Octopus Asset Management Limited ("Octopus") whereby MMI has
sold its interests in the VCT to enable it to focus on its core business of
developing its portfolio of therapeutics.



MMI announced on 9 March 2006 that it had reached conditional agreement with VCT
and Octopus whereby MMI would cease to provide services to VCT and forego its
carried interest in the VCT. In return, the VCT and Octopus had agreed to:



*         Pay MMI an undisclosed sum

*         Indemnify, keep indemnified and hold MMI harmless from and against
liabilities arising out of and/or in connection with the services, except for
any investment decisions made by the VCT after relying solely on due diligence
performed by MMI

*         Table a resolution at the Annual General Meeting of the VCT for the
purpose of considering changing the company name to exclude the word
" Bioscience "  (which is associated with MMI) with a recommendation from
directors of the VCT for shareholders to vote in favour of the resolution



Following the passing of the resolution at yesterday's AGM of the VCT to change
the name of the VCT from Bioscience VCT to Hygea VCT plc, the agreement between
MMI, Octopus and VCT has become unconditional.



David Best Chairman of MMI commenting on this announcement said: "This agreement
now enables MMI to focus solely on its successful core business of developing
and commercialising its expanding portfolio of therapies for cancer and
infection."





For further information, please contact:


David Best  ?c=8211  Executive Chairman
MMI Group                                                Tel: +44 (0)1223 477677
www.mmigroup.co.uk

Lisa Baderoon / Rebecca Skye Dietrich
Buchanan Communications                                 Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRUKAWRNVRSAAR

1 Year Bioscience Vct Chart

1 Year Bioscience Vct Chart

1 Month Bioscience Vct Chart

1 Month Bioscience Vct Chart

Your Recent History

Delayed Upgrade Clock